bupivacaine has been researched along with Encephalopathy, Toxic in 42 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The anesthetic bupivacaine (Bup) has been reported to induce neurotoxicity mediated by reactive oxygen species (ROS), which is aggravated by hyperglycemia." | 8.02 | KLF9 regulates PRDX6 expression in hyperglycemia-aggravated bupivacaine neurotoxicity. ( Lai, L; Lei, H; Li, H; Li, L; Weng, Y; Xu, S; Zhang, Y, 2021) |
| " In the current study, we explored the mechanisms by which microRNA-132 (miR-132) regulated the neurotoxicity of human neuroblastoma cells (SH-SY5Y) induced by bupivacaine (BUP)." | 7.91 | Effect of miR-132 on bupivacaine-induced neurotoxicity in human neuroblastoma cell line. ( He, Q; Hu, T; Lin, J; Ren, Z; Wang, W; Zhang, H, 2019) |
| "LLLT, at the dose used, reduced fibrosis and myonecrosis in the sternomastoid muscle triggered by bupivacaine, accelerating the muscle regeneration process." | 7.85 | Low-level laser therapy (LLLT) accelerates the sternomastoid muscle regeneration process after myonecrosis due to bupivacaine. ( Alessi Pissulin, CN; Henrique Fernandes, AA; Michelin Matheus, SM; Rossi E Silva, RC; Sanchez Orellana, AM, 2017) |
| " The anesthetic bupivacaine (Bup) has been reported to induce neurotoxicity mediated by reactive oxygen species (ROS), which is aggravated by hyperglycemia." | 4.02 | KLF9 regulates PRDX6 expression in hyperglycemia-aggravated bupivacaine neurotoxicity. ( Lai, L; Lei, H; Li, H; Li, L; Weng, Y; Xu, S; Zhang, Y, 2021) |
| " In the current study, we explored the mechanisms by which microRNA-132 (miR-132) regulated the neurotoxicity of human neuroblastoma cells (SH-SY5Y) induced by bupivacaine (BUP)." | 3.91 | Effect of miR-132 on bupivacaine-induced neurotoxicity in human neuroblastoma cell line. ( He, Q; Hu, T; Lin, J; Ren, Z; Wang, W; Zhang, H, 2019) |
| "LLLT, at the dose used, reduced fibrosis and myonecrosis in the sternomastoid muscle triggered by bupivacaine, accelerating the muscle regeneration process." | 3.85 | Low-level laser therapy (LLLT) accelerates the sternomastoid muscle regeneration process after myonecrosis due to bupivacaine. ( Alessi Pissulin, CN; Henrique Fernandes, AA; Michelin Matheus, SM; Rossi E Silva, RC; Sanchez Orellana, AM, 2017) |
| "Fentanyl 20 micro g was added to both local anesthetics, and the total volume was diluted to 3 mL with 0." | 2.71 | Subarachnoid small-dose bupivacaine versus lidocaine for cervical cerclage. ( Abramovitz, S; Beilin, Y; Bernstein, HH; Bodian, C; Hossain, S; Zahn, J, 2003) |
| "Chloroprocaine has been demonstrated to be associated with a lower risk of transient neurologic symptoms compared with lidocaine." | 2.50 | Spinal anesthesia revisited: toxicity of new and old drugs and compounds. ( Hampl, K; Steinfeldt, T; Wulf, H, 2014) |
| "The duration of postsurgical pain greatly outlasts the duration of analgesia (typically < 12 h) following single administration of traditional formulations of local anesthetics." | 2.49 | Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. ( Ilfeld, BM, 2013) |
| "Bupivacaine (BUP) has previously been shown to trigger neurotoxicity after spinal anesthesia." | 1.91 | Ferrostatin-1 ameliorates Bupivacaine-Induced spinal neurotoxicity in rats by inhibiting ferroptosis. ( Chen, Y; Ji, J; Lai, J; Lin, Y; Liu, J; Liu, Z; Luo, X; Luo, Y; Wei, L; Zhao, Y; Zhou, G, 2023) |
| "Melatonin (MT), is a potent neuroprotective molecule." | 1.72 | Melatonin ameliorates bupivacaine-induced spinal neurotoxicity in rats by suppressing neuronal NLRP3 inflammasome activation. ( Chen, MY; Huang, LS; Ji, JM; Lai, J; Liu, JC; Luo, YP; Wei, LL; Yu, Y; Zhou, G, 2022) |
| "Bupivacaine (BUP) is a long-acting amide local anesthetic that may induce strong neurotoxicity and neurological complications." | 1.62 | MiRNA-494-3p Regulates Bupivacaine-Induced Neurotoxicity by the CDK6-PI3K/AKT Signaling. ( Guo, F; Zhang, L, 2021) |
| "Bupivacaine has been widely used in clinical Anesthesia, but its neurotoxicity has been frequently reported, implicating cellular oxidative DNA damage as the major underlying mechanism." | 1.62 | The roles of PARP-1 and XPD and their potential interplay in repairing bupivacaine-induced neuron oxidative DNA damage. ( Lai, L; Liu, Z; Luo, J; Ma, C; Xia, Z; Xu, S; Zhao, W, 2021) |
| " Any substances that can mitigate the toxic effects of BV are of great importance in surgical procedures and pain management." | 1.62 | Hesperidin alleviates bupivacaine anesthesia-induced neurotoxicity in SH-SY5Y cells by regulating apoptosis and oxidative damage. ( Wang, T; Zhang, W; Zheng, L, 2021) |
| "Subarachnoid administration of liposomal bupivacaine in pigs exhibited a dose-response effect, and resulted in longer duration of neuraxial block than bupivacaine hydrochloride without histological evidence of neurotoxicity." | 1.51 | Neurological and histological outcomes after subarachnoid injection of a liposomal bupivacaine suspension in pigs: a pilot study. ( Cvetko, E; Damjanovska, M; Hadzic, A; Kuroda, MM; Sega Jazbec, S; Seliskar, A; Stopar Pintaric, T; Zel, J, 2019) |
| "Bupivacaine has been shown to induce neurotoxicity through inducing excessive reactive oxygen species (ROS), but the underlying mechanism remains unclear." | 1.46 | Activation of p47phox as a Mechanism of Bupivacaine-Induced Burst Production of Reactive Oxygen Species and Neural Toxicity. ( Li, FX; Li, L; Li, YJ; Liu, ZT; Xu, SY; Yu, XJ; Zhao, W, 2017) |
| "Bupivacaine is a local anesthetic widely used in surgical procedures." | 1.43 | Comparison of histopathological effects of perineural administration of bupivacaine and bupivacaine-dexmedetomidine in rat sciatic nerve. ( Alizadeh, L; Arhami-Dolatabadi, A; Daneshbod, Y; Hosseinian, MA; Khandaghy, M; Memari, E; Mirabotalebi, M; Mirkheshti, A; Shirian, S, 2016) |
| "Ropivacaine is not safe when intrathecally administered with lidocaine at the concentrations used in this study." | 1.40 | Intrathecal lidocaine neurotoxicity: combination with bupivacaine and ropivacaine and effect of nerve growth factor. ( Chen, W; Ding, X; Guo, Y; Zhao, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (19.05) | 29.6817 |
| 2010's | 22 (52.38) | 24.3611 |
| 2020's | 12 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 2 |
| Guo, F | 1 |
| Lai, J | 2 |
| Ji, JM | 1 |
| Chen, MY | 1 |
| Luo, YP | 1 |
| Yu, Y | 1 |
| Zhou, G | 2 |
| Wei, LL | 1 |
| Huang, LS | 1 |
| Liu, JC | 1 |
| Zhao, Y | 2 |
| Luo, Y | 1 |
| Liu, Z | 4 |
| Chen, Y | 1 |
| Wei, L | 1 |
| Luo, X | 2 |
| Ji, J | 3 |
| Lin, Y | 1 |
| Liu, J | 3 |
| Wang, Y | 1 |
| Lai, L | 3 |
| Guo, W | 1 |
| Peng, S | 1 |
| Liu, R | 1 |
| Hong, P | 1 |
| Wei, G | 1 |
| Li, F | 1 |
| Jiang, S | 1 |
| Wang, P | 1 |
| Li, J | 1 |
| Lei, H | 2 |
| Zhao, W | 5 |
| Xu, S | 4 |
| Nie, H | 1 |
| Bai, Z | 1 |
| Li, Z | 2 |
| Yan, L | 1 |
| Chen, XX | 1 |
| Ji, ZH | 1 |
| Zhou, Y | 1 |
| Wang, H | 2 |
| Li, S | 1 |
| Liang, GQ | 1 |
| Mao, J | 1 |
| Guan, L | 1 |
| Li, T | 1 |
| Jiang, J | 1 |
| Ji, Z | 1 |
| Xu, H | 1 |
| Xia, Z | 2 |
| Xu, R | 1 |
| Yuning, F | 1 |
| Liang, C | 1 |
| Tenghuan, W | 1 |
| Zhenhua, N | 1 |
| Shengkai, G | 1 |
| Luo, J | 1 |
| Ma, C | 1 |
| Li, H | 1 |
| Weng, Y | 1 |
| Zhang, Y | 1 |
| Li, L | 2 |
| Wang, T | 1 |
| Zheng, L | 1 |
| Zhang, W | 1 |
| Guo, J | 1 |
| Tao, Q | 1 |
| Sun, S | 1 |
| Liu, L | 2 |
| Zhang, J | 1 |
| Yang, D | 1 |
| Lim, WY | 1 |
| Wijeratne, SA | 1 |
| Lim, EHL | 1 |
| Li, YJ | 1 |
| Yu, XJ | 1 |
| Li, FX | 1 |
| Liu, ZT | 1 |
| Xu, SY | 2 |
| Chen, L | 1 |
| Wang, X | 1 |
| Huang, W | 1 |
| Ying, T | 1 |
| Chen, M | 1 |
| Cao, J | 1 |
| Wang, M | 1 |
| Zel, J | 1 |
| Hadzic, A | 1 |
| Cvetko, E | 1 |
| Seliskar, A | 1 |
| Damjanovska, M | 1 |
| Kuroda, MM | 1 |
| Sega Jazbec, S | 1 |
| Stopar Pintaric, T | 1 |
| Zhang, H | 1 |
| Lin, J | 1 |
| Hu, T | 1 |
| Ren, Z | 1 |
| Wang, W | 1 |
| He, Q | 1 |
| Liu, B | 1 |
| Feng, Q | 1 |
| Yan, X | 2 |
| Ni, Y | 1 |
| He, Y | 1 |
| Mao, Z | 1 |
| Ai, Y | 1 |
| Ilfeld, BM | 1 |
| Vadi, MG | 1 |
| Patel, N | 1 |
| Stiegler, MP | 1 |
| Hampl, K | 1 |
| Steinfeldt, T | 1 |
| Wulf, H | 1 |
| Zhao, G | 1 |
| Ding, X | 1 |
| Guo, Y | 1 |
| Chen, W | 1 |
| Lai, Z | 1 |
| Chen, X | 1 |
| Xu, Z | 1 |
| Lin, R | 1 |
| Fan, YL | 1 |
| Li, HC | 1 |
| Peng, HH | 1 |
| Huang, F | 1 |
| Jiang, WH | 1 |
| Memari, E | 1 |
| Hosseinian, MA | 1 |
| Mirkheshti, A | 1 |
| Arhami-Dolatabadi, A | 1 |
| Mirabotalebi, M | 1 |
| Khandaghy, M | 1 |
| Daneshbod, Y | 1 |
| Alizadeh, L | 1 |
| Shirian, S | 1 |
| Alessi Pissulin, CN | 1 |
| Henrique Fernandes, AA | 1 |
| Sanchez Orellana, AM | 1 |
| Rossi E Silva, RC | 1 |
| Michelin Matheus, SM | 1 |
| Brummett, CM | 1 |
| Norat, MA | 1 |
| Palmisano, JM | 1 |
| Lydic, R | 1 |
| Hung, CH | 1 |
| Liu, KS | 1 |
| Shao, DZ | 1 |
| Cheng, KI | 1 |
| Chen, YC | 1 |
| Chen, YW | 1 |
| Wolfe, JW | 1 |
| Butterworth, JF | 1 |
| Wang, Z | 1 |
| Shen, J | 1 |
| Wang, J | 1 |
| Lu, T | 1 |
| Li, C | 1 |
| Zhang, X | 1 |
| Ding, Z | 1 |
| Takenami, T | 1 |
| Wang, G | 1 |
| Nara, Y | 1 |
| Fukushima, S | 1 |
| Yagishita, S | 1 |
| Hiruma, H | 1 |
| Kawakami, T | 1 |
| Okamoto, H | 1 |
| Birkelund, T | 1 |
| Revenfeld, TS | 1 |
| Møller, JF | 1 |
| Beilin, Y | 1 |
| Zahn, J | 1 |
| Abramovitz, S | 1 |
| Bernstein, HH | 1 |
| Hossain, S | 1 |
| Bodian, C | 1 |
| Punke, MA | 1 |
| Friederich, P | 1 |
| Casati, A | 1 |
| Putzu, M | 1 |
| Sakura, S | 1 |
| Kirihara, Y | 1 |
| Muguruma, T | 1 |
| Kishimoto, T | 1 |
| Saito, Y | 1 |
| Zimmer, C | 1 |
| Piepenbrink, K | 1 |
| Riest, G | 1 |
| Peters, J | 1 |
| Markey, JR | 1 |
| Naseer, OB | 1 |
| Bird, DJ | 1 |
| Rabito, SF | 1 |
| Winnie, AP | 1 |
| Rorarius, M | 1 |
| Suominen, P | 1 |
| Haanpaa, M | 1 |
| Puura, A | 1 |
| Baer, G | 1 |
| Pajunen, P | 1 |
| Tuimala, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block on Postoperative Delirium and Long-term Oucomes in Elderly Patients After Single Knee Arthroplasty[NCT03629483] | Phase 4 | 736 participants (Anticipated) | Interventional | 2018-12-10 | Suspended (stopped due to Trial stopped by the sponsor because of no funding.) | ||
| Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial[NCT04961281] | 60 participants (Actual) | Interventional | 2021-07-22 | Completed | |||
| The Effect of Dexamedetomidine for Interscalene Brachial Plexus Block on Plasma Cortisol and IL-6 After Rotator Cuff Repair: a Prospective Randomized Study[NCT02766556] | 50 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Fractional Carbon Dioxide Laser Assisted Delivery of Topical Anesthetics: a Randomized Controlled Pilot Study[NCT02246179] | Phase 4 | 10 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Parameters in Fractional Laser Assisted Delivery of Topical Anesthetics: Role of Anesthetic and Application Time[NCT03279757] | Phase 4 | 15 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| Parameters in Fractional Laser Assisted Delivery of Topical Anesthetics: Role of Laser Type and Laser Settings[NCT02938286] | Phase 4 | 15 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Fractional CO2 Laser Assisted Topical Articaine Anesthesia vs. Topical EMLA Administration: a Randomized Controlled Study[NCT02548533] | Phase 4 | 3 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Not enough patients eligible for recruitment.) | ||
| Prospective Randomized Trial of Penile Nerve Block With Liposomal Bupivacaine for Hypospadias Repair vs Standard Penile Block With Bupivacaine[NCT04479371] | Phase 1 | 0 participants (Actual) | Interventional | 2021-07-31 | Withdrawn (stopped due to Limited funding and resources to complete FDA requirements for enrollment) | ||
| Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial[NCT02517996] | 18 participants (Actual) | Interventional | 2015-02-28 | Terminated (stopped due to Preliminary results were promising when interim analysis performed but terminated due to primary investigators left recruitment site.) | |||
| A Randomized Controlled Clinical Trial of Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage[NCT03305575] | Phase 4 | 10 participants (Actual) | Interventional | 2017-10-13 | Completed | ||
| High Thoracic Epidural Anesthesia and Postoperative Analgesia With Ropivacaine or Levobupivacaine for Coronary Surgery: A Prospective Randomized Double-Blind Comparison[NCT00552864] | Phase 4 | 61 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To determine the change in interstitial cystitis symptom index at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The IC symptom index questionnaire consists of 4 questions on IC symptoms. 2 of the questions have 6 answer choices ranging from 0-never, to 5-almost always. 1 question has 6 answer choices ranging from 0-never to 5-usually. 1 question has 7 answer choices ranging from 0-never to 6-5 or more times. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 21. A higher score indicates greater severity of IC symptoms." (NCT02517996)
Timeframe: Baseline, 2 weeks, 6 weeks, 3 months (Up to 3 months)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 2 weeks | 6 weeks | 12 weeks | |
| 1% Lidocaine | 12.5 | 11.43 | 11.8 | 10 |
| Normal Saline | 10 | 9 | 8.67 | 5 |
"To determine the change in pain at 2 hours, 2 weeks, 6 weeks, and 3 months postoperatively in patients undergoing hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline) using the visual analog scale (VAS).~VAS consists of a 10cm horizontal line with the minimum endpoint labeled no pain (0) and maximum labeled worst pain ever (10). Patients placed a mark on the point that corresponds to the level of pain severity they felt. The cm distance from the low end of the VAS to the patient's mark is used as the numerical index of the intensity of pain. Pain scores of 3.0-5.4 cm are moderate, over 5.4 indicates severe pain." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Pre operative VAS score | Post operative VAS score | 2 week post operative VAS scores | 6 week post operative VAS score | 12 weeks post operative VAS score | |
| 1% Lidocaine | 3.125 | 3.75 | 2.7 | 3 | 2.6 |
| Normal Saline | 4.5 | 5 | 4.8 | 4.33 | 2 |
"To determine the change in pelvic urgency, pain and frequency (PUF) questionnaire at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The Pelvic Urgency, Pain, and Frequency Patient Symptom Scale asks 11 questions, 7 on PUF symptoms, 4 on how bothersome PUF symptoms are. Symptom questions include 3, 4, or 5 ranked answers, with higher answers indicating more voids, or greater frequency of pain. The bother questions each of 4 ranked answers from 0-never, to 3-always. The symptom score is added, the bother score is added, and then the total score is added. The total PUF score is then reported. The minimum score is 0 and the maximum score is 35, and a higher score indicates greater symptoms and higher bother from pelvic pain and frequency." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 2 weeks | 6 weeks | 12 weeks | |
| 1% Lidocaine | 22.63 | 18.83 | 18.2 | 17.2 |
| Normal Saline | 19 | 17.4 | 16.7 | 14 |
"To determine the change in problem index (O'Leary Sant) at baseline, 2 hours, 2 weeks, 6 weeks and 3 months after hydrodistention with preemptive pudendal nerve block (1% Lidocaine) compared to hydrodistention with placebo (saline).~The IC problem index questionnaire consists of 4 questions on how much of a problem a patient's IC symptoms cause them. Each question has 5 answer choices ranging from 0-no problem, to 4-big problem. The numerical score for each question are added together, with a minimum score of 0 and a maximum score of 16. A higher score indicates that IC symptoms cause more problems for the patient." (NCT02517996)
Timeframe: Baseline, 2 hours, 2 weeks, 6 weeks, 3 months (Up to 3 months)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 2 weeks | 6 weeks | 12 weeks | |
| 1% Lidocaine | 11.75 | 9.71 | 10 | 9.6 |
| Normal Saline | 9.43 | 8.6 | 7.33 | 6 |
"The time difference between local anesthetic injection and complete resolution of motor block -as measured on the Bromage scale:~I = free movement of feet, legs and hip = No block II = able to flex knees, with free movement of feet = Mild block III = unable to flex knees, but with free movement of feet = Moderate block IV = unable to move legs or feet = Complete block" (NCT03305575)
Timeframe: 6 hours
| Intervention | minutes (Mean) |
|---|---|
| Chloroprocaine | 75 |
| Bupivacaine | 99 |
The time difference between local anesthetic injection and complete resolution of sensory block. The sensory level was tested using a blunt needle tip along the patient's demratomal distribution of the spinal anesthetic. (NCT03305575)
Timeframe: 6 hours
| Intervention | minutes (Mean) |
|---|---|
| Chloroprocaine | 127 |
| Bupivacaine | 210 |
The time difference between local anesthetic injection and patient's walking for the first time postoperatively. (NCT03305575)
Timeframe: 6 hours
| Intervention | minutes (Mean) |
|---|---|
| Chloroprocaine | 110 |
| Bupivacaine | 179 |
The time difference between local anesthetic injection and the patient's voiding for the first time postoperatively. (NCT03305575)
Timeframe: 6 hours
| Intervention | minutes (Mean) |
|---|---|
| Chloroprocaine | 111 |
| Bupivacaine | 233 |
4 reviews available for bupivacaine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain.
Topics: Anesthetics, Local; Animals; Bupivacaine; Humans; Injections, Epidural; Liposomes; Muscular Diseases | 2013 |
Spinal anesthesia revisited: toxicity of new and old drugs and compounds.
Topics: Anesthesia, Spinal; Anesthetics, Local; Bupivacaine; Humans; Levobupivacaine; Lidocaine; Neurotoxici | 2014 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Local anesthetic systemic toxicity: update on mechanisms and treatment.
Topics: Anesthesia, Local; Anesthetics, Local; Animals; Bupivacaine; Cardiovascular Diseases; Disease Models | 2011 |
Bupivacaine, levobupivacaine and ropivacaine: are they clinically different?
Topics: Amides; Anesthetics, Local; Bupivacaine; Humans; Levobupivacaine; Neurotoxicity Syndromes; Ropivacai | 2005 |
2 trials available for bupivacaine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Subarachnoid small-dose bupivacaine versus lidocaine for cervical cerclage.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Spinal; Anesthetics, Intravenous; Anesthetics, Local; Bupiv | 2003 |
Neurologic sequelae after caesarean section.
Topics: Adolescent; Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthetics, Local; Bupivacaine; C | 2001 |
36 other studies available for bupivacaine and Encephalopathy, Toxic
| Article | Year |
|---|---|
MiRNA-494-3p Regulates Bupivacaine-Induced Neurotoxicity by the CDK6-PI3K/AKT Signaling.
Topics: Animals; Blotting, Western; Bupivacaine; Cyclin-Dependent Kinase 6; Flow Cytometry; Hippocampus; Mic | 2021 |
Melatonin ameliorates bupivacaine-induced spinal neurotoxicity in rats by suppressing neuronal NLRP3 inflammasome activation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Bupivacaine; Male; Melatonin; Microglia; Neurons; N | 2022 |
Ferrostatin-1 ameliorates Bupivacaine-Induced spinal neurotoxicity in rats by inhibiting ferroptosis.
Topics: Animals; Bupivacaine; Ferroptosis; Glutathione; Neurotoxicity Syndromes; Rats; Spinal Cord | 2023 |
Inhibition of Ku70 in a high-glucose environment aggravates bupivacaine-induced dorsal root ganglion neurotoxicity.
Topics: Anesthetics, Local; Animals; Apoptosis; Bupivacaine; Cells, Cultured; Chromones; DNA Damage; Enzyme | 2020 |
Intravenous lipid emulsion modifies synaptic transmission in hippocampal CA1 pyramidal neurons after bupivacaine-induced central nervous system toxicity.
Topics: Anesthetics, Local; Animals; Bupivacaine; CA1 Region, Hippocampal; Fat Emulsions, Intravenous; Male; | 2020 |
Inhibition of DNA Repair Protein Ku70 in High-Glucose Environment Aggravates the Neurotoxicity Induced by Bupivacaine in SH-SY5Y Cells.
Topics: Apoptosis; Bupivacaine; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Gene Exp | 2020 |
Bupivacaine-Induced Neurotoxicity Is Modulated by Epigenetic Axis of Long Noncoding RNA SNHG16 and Hsa-miR-132-3p.
Topics: Anesthetics, Local; Apoptosis; Bupivacaine; Cell Line, Tumor; Cell Survival; Epigenesis, Genetic; Hu | 2020 |
Mechanistic study of mtROS-JNK-SOD2 signaling in bupivacaine-induced neuron oxidative stress.
Topics: Acetylcysteine; Animals; Anthracenes; Antioxidants; Bupivacaine; Cell Line, Tumor; Cyclic N-Oxides; | 2020 |
Knockdown of lincRNA PADNA promotes bupivacaine-induced neurotoxicity by miR-194/FBXW7 axis.
Topics: 3' Untranslated Regions; Anesthetics, Local; Animals; Apoptosis; Bupivacaine; Cell Line; Cell Surviv | 2020 |
The roles of PARP-1 and XPD and their potential interplay in repairing bupivacaine-induced neuron oxidative DNA damage.
Topics: Anesthetics, Local; Apoptosis; Bupivacaine; Cell Line, Tumor; DNA Repair; Humans; Neurons; Neurotoxi | 2021 |
KLF9 regulates PRDX6 expression in hyperglycemia-aggravated bupivacaine neurotoxicity.
Topics: Bupivacaine; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Humans; Hyperglycemia; Krupp | 2021 |
Hesperidin alleviates bupivacaine anesthesia-induced neurotoxicity in SH-SY5Y cells by regulating apoptosis and oxidative damage.
Topics: Anesthetics, Local; Apoptosis; Bupivacaine; Cell Line, Tumor; Hesperidin; Humans; Neurotoxicity Synd | 2021 |
Antidepressant Imipramine Protects Bupivacaine-Induced Neurotoxicity in Dorsal Root Ganglion Neurons Through Coactivation of TrkA and TrkB.
Topics: Animals; Antidepressive Agents; Bupivacaine; Enzyme Activation; Ganglia, Spinal; Imipramine; Mice; N | 2017 |
Awake caudal anaesthesia in neonates/young infants for improved patient safety.
Topics: Adenosine; Adjuvants, Anesthesia; Anesthesia, Caudal; Anti-Arrhythmia Agents; Bupivacaine; Fat Emuls | 2017 |
Activation of p47phox as a Mechanism of Bupivacaine-Induced Burst Production of Reactive Oxygen Species and Neural Toxicity.
Topics: Animals; Benzoxazoles; Bupivacaine; Cell Line, Tumor; Cell Membrane; Male; NADPH Oxidases; Neurotoxi | 2017 |
MicroRNA-137 and its downstream target LSD1 inversely regulate anesthetics-induced neurotoxicity in dorsal root ganglion neurons.
Topics: Anesthetics; Animals; Bupivacaine; Disease Models, Animal; Down-Regulation; Ganglia, Spinal; Histone | 2017 |
Neurological and histological outcomes after subarachnoid injection of a liposomal bupivacaine suspension in pigs: a pilot study.
Topics: Anesthetics, Local; Animals; Bupivacaine; Delayed-Action Preparations; Disease Models, Animal; Dose- | 2019 |
Effect of miR-132 on bupivacaine-induced neurotoxicity in human neuroblastoma cell line.
Topics: Anesthetics, Local; Apoptosis; Bupivacaine; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; | 2019 |
Monosialoganglioside protects against bupivacaine-induced neurotoxicity caused by endoplasmic reticulum stress in rats.
Topics: Animals; Bupivacaine; Endoplasmic Reticulum Stress; Gangliosides; Male; Neuroprotective Agents; Neur | 2019 |
Knockdown of lncRNA MALAT1 alleviates bupivacaine-induced neurotoxicity via the miR-101-3p/PDCD4 axis.
Topics: Anesthetics, Local; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bupivacaine; Cell Line, Tumor | 2019 |
Local anesthetic systemic toxicity after combined psoas compartment-sciatic nerve block: analysis of decision factors and diagnostic delay.
Topics: Aged, 80 and over; Anesthetics, Local; Bradycardia; Bupivacaine; Delayed Diagnosis; Epilepsy, Tonic- | 2014 |
Intrathecal lidocaine neurotoxicity: combination with bupivacaine and ropivacaine and effect of nerve growth factor.
Topics: Amides; Anesthetics, Local; Animals; Apoptosis; Bupivacaine; Caspase 3; Down-Regulation; Drug Combin | 2014 |
Therapeutic effects of intrathecal versus intravenous monosialoganglioside against bupivacaine-induced spinal neurotoxicity in rats.
Topics: Animals; Axons; Blood-Brain Barrier; Bupivacaine; Caspase 3; Gangliosides; Hot Temperature; Immunohi | 2015 |
Persistent cauda equina syndrome after cesarean section under combined spinal-epidural anesthesia: a case report.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Local; Arachn | 2015 |
Curcumin Attenuated Bupivacaine-Induced Neurotoxicity in SH-SY5Y Cells Via Activation of the Akt Signaling Pathway.
Topics: Apoptosis; Bupivacaine; Cell Line, Tumor; Cell Survival; Curcumin; Humans; Membrane Potential, Mitoc | 2016 |
Comparison of histopathological effects of perineural administration of bupivacaine and bupivacaine-dexmedetomidine in rat sciatic nerve.
Topics: Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Disease Models, Animal; Microscopy, Elect | 2016 |
Low-level laser therapy (LLLT) accelerates the sternomastoid muscle regeneration process after myonecrosis due to bupivacaine.
Topics: Animals; Bupivacaine; Fibrosis; Low-Level Light Therapy; Muscular Diseases; Neck Muscles; Necrosis; | 2017 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.
Topics: Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Dose-Response R | 2008 |
The systemic toxicity of equipotent proxymetacaine, oxybuprocaine, and bupivacaine during continuous intravenous infusion in rats.
Topics: Analgesia; Anesthetics, Local; Animals; Bupivacaine; Dose-Response Relationship, Drug; Hemodynamics; | 2010 |
Lithium attenuates bupivacaine-induced neurotoxicity in vitro through phosphatidylinositol-3-kinase/threonine-serine protein kinase B- and extracellular signal-regulated kinase-dependent mechanisms.
Topics: Anesthetics, Local; Animals; Blotting, Western; Bupivacaine; Cell Line; Extracellular Signal-Regulat | 2012 |
Intrathecally administered ropivacaine is less neurotoxic than procaine, bupivacaine, and levobupivacaine in a rat spinal model.
Topics: Amides; Anesthetics, Local; Animals; Axons; Behavior, Animal; Bupivacaine; Dose-Response Relationshi | 2012 |
[Transient segmental hyperalgesia following epidural analgesia].
Topics: Adult; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Catheterization; Di | 2012 |
Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
Topics: Anesthetics, Local; Animals; Bupivacaine; Carbamates; CHO Cells; Cricetinae; Humans; KCNQ2 Potassium | 2004 |
The comparative neurotoxicity of intrathecal lidocaine and bupivacaine in rats.
Topics: Anesthetics, Local; Animals; Bupivacaine; Chemistry, Pharmaceutical; Dose-Response Relationship, Dru | 2005 |
[Cardiotoxic and neurotoxic effects after accidental intravascular bupivacaine administration. Therapy with lidocaine propofol and lipid emulsion].
Topics: Aged, 80 and over; Anesthesia, Epidural; Anesthetics, Intravenous; Anesthetics, Local; Blood Pressur | 2007 |
Transient neurologic symptoms after epidural analgesia.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Bupivacaine; Female; Humans; | 2000 |